Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. (Q53792585)
Jump to navigation
Jump to search
scientific article published on 5 May 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. |
scientific article published on 5 May 2016 |
Statements
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. (English)
1 reference
1 reference
Margaret von Mehren
1 reference
Andrew J Wagner
1 reference
Mark Agulnik
1 reference
Daruka Mahadevan
1 reference
Richard F Riedel
1 reference
Jonathan Trent
1 reference
George D Demetri
1 reference
Christopher L Corless
1 reference
Murray Yule
1 reference
John F Lyons
1 reference
Aram Oganesian
1 reference
Harold Keer
1 reference
5 May 2016
1 reference
61
1 reference
94-101
1 reference
Identifiers
1 reference